DEC 24, 2015 10:32 AM PST

Immunotherapy Better for Non-Small-Cell Lung Cancer Patients

WRITTEN BY: Kara Marker
Some tumor cells in patients with non-small-cell lung cancer (NSCLC) express programmed death ligand 1 (PD-L1) that binds to its receptor (PD-1) which is expressed by immune cells. This interaction inhibits T cells’ ability to attack cancerous cells, allowing the tumor to grow unimpeded (Oncology). In attempt to block this inhibition, scientists are developing an immunotherapy that targets PD-1 and allows T cells to properly fight off growing cancer cells.

From the University of California, Los Angeles, researchers studied a group of patients with NSCLC to see how PD-1 immunotherapy compares with traditional chemotherapy.  Out of over a thousand participants, 75 percent had at least one percent of PD-L1 expressed by their tumor cells. The study results, which were published in The Lancet, showed groups of NSCLC patients receiving the PD-1 immunotherapy both experienced significant tumor shrinkage and lived longer than the patients who received chemotherapy.

"For most patients, this now offers data showing that immunotherapy leads to superior clinical outcomes with a side effect profile that is generally favorable to our traditional therapies," said Dr. Edward Garon, senior author of the paper.

Indeed, PD-1 immunotherapy utilizes the antibody pembrolizumab, which is significantly less toxic to cancer patients than chemicals used in chemotherapy.

NSCLC like squamous cell carcinoma, adenocarcinoma, and large cell carcinoma are the most common types of lung cancer, making up 85 percent of all cases of lung cancer (American Cancer Society). Lung cancer is the leading cause of cancer death.

"This treatment provides real hope of long-lasting responses," Garon added.

For more about lung cancer, watch the following video.

Source: University of California, Los Angeles
 
About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
OCT 29, 2018
Immunology
OCT 29, 2018
Escape of the Tumor Cell
Tumor cells in breast cancer have proven to evade the immune responses utilizing actin cytoskeleton...
OCT 30, 2018
Drug Discovery
OCT 30, 2018
Re-sensitizing Drug-resistant Human Tumor Cells
Understanding how cancer cells avoid death despite their DNA being damaged will create new strategies to enhance cancer cell killing through chemotherapy t...
NOV 27, 2018
Immunology
NOV 27, 2018
A Genetic Switch During Inflammation
Microglia, CNS immune cells, change their genetic profile during different states of the inflammation spectrum...
NOV 28, 2018
Immunology
NOV 28, 2018
A Rewind on Autoimmunity
Enzymes identified that are responsible for methylation that will play a role in the production of immune cytokine molecules...
DEC 10, 2018
Health & Medicine
DEC 10, 2018
Sarcoidosis: Severe Infections and Complications
  Sarcoidosis is characterized by an exaggerated immune response to an unrecognized antigen, which has not yet been identified. It is an inflammatory...
DEC 20, 2018
Health & Medicine
DEC 20, 2018
Common Medication Regimens for Sarcoidosis
Sarcoidosis is a granulomatous disease that most commonly affects the lungs, but any organ system can be involved. It is most often found and diagnosed in...
Loading Comments...